KRAS ^G12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma.

ABSTRACT:

Purpose

KRAS ^G12C is the most common KRAS mutation in primary lung adenocarcinoma. Phase I clinical trials have demonstrated encouraging clinical activity of KRAS ^G12C inhibitors in the metastatic setting. We investigated disease-free survival (DFS) and tumor genomic features in patients with surgically resected KRAS ^G12C-mutant lung adenocarcinoma.

Experimental design

Patients who underwent resection of stage I-III lung adenocarcinoma and next-generation sequencing (NGS) were evaluated. Exclusion criteria were receipt of induction therapy, incomplete resection, and low-quality NGS. Mutations were classified as KRAS wild-type (KRAS ^wt), G12C (KRAS ^G12C), or non-G12C (KR

SUBMITTER: Jones GD 

PROVIDER: S-EPMC8102372 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature